Showing results (91-100 of 118) with videos related to

Sort By:
Pageof 12
Diabetes Care|October 14, 2025
Updating a Clinical Prediction Model for Identifying Monogenic Diabetes to Include Both Clinical Features and BiomarkersJulieanne Knupp, Pedro Cardoso, Katherine G Young, et al.
The Lancet. Primary Care|May 11, 2026
Kidney outcomes with GLP-1 receptor agonists in people with type 2 diabetes already receiving SGLT2 inhibitors: a target trial emulation study using UK primary care dataThijs T Jansz, Andrew P McGovern, Katherine G Young, et al.
Diabetologia|June 5, 2024
Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approachLaura M Güdemann, Katie G Young, Nicholas J M Thomas, et al.
Lancet (London, England)|February 28, 2025
A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation studyJohn M Dennis, Katherine G Young, Pedro Cardoso, et al.
Diabetes Care|August 4, 2018
Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial DataJohn M Dennis, William E Henley, Michael N Weedon, et al.
Diabetes Care|May 20, 2026
Precision Prescribing of SGLT2 Inhibitors in Individuals With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation StudyKatherine G Young, Andrew P McGovern, Rhian Hopkins, et al.
Diabetes Care|February 2, 2018
Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor TherapyJohn M Dennis, Beverley M Shields, Anita V Hill, et al.
Journal of Diabetes Investigation|August 21, 2023
Incretin hormone responses to carbohydrate and protein/fat are preserved in adults with sulfonylurea-treated KCNJ11 neonatal diabetesPamela Bowman, Kashyap A Patel, Timothy J McDonald, et al.
The Lancet. Digital Health|November 25, 2022
Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort studyJohn M Dennis, Katherine G Young, Andrew P McGovern, et al.
Journal of Medical Genetics|November 29, 2013
The HNF4A R76W mutation causes atypical dominant Fanconi syndrome in addition to a β cell phenotypeAlexander J Hamilton, Coralie Bingham, Timothy J McDonald, et al.
Pageof 12